ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Acceleron receives FDA breakthrough therapy designation for sotatercept in pulmonary arterial hypertension
April 14, 2020Acceleron Pharma announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH). -
Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS
April 07, 2020Bristol Myers Squibb (BMS) and Acceleron Pharma have secured approval from the US Food and Drug Administration (FDA) for Reblozyl (luspatercept-aamt) to treat anaemia in adults with lower-risk myelodysplastic syndromes (MDS).
Pharma Sources Insight January 2025
